Economic Audit - Aviva plc

Domain: Economic (Economic) Entity scope: Aviva plc (LSE: AV.) and Aviva Investors. Active/discretionary holdings are distinguished from passive index exposure held on behalf of clients throughout. Compiled: 2026-06-21 Method: Live web search only

Supply Chain & Sourcing Relationships

Aviva is a financial-services group, not a manufacturer; its supply chain comprises professional services, IT, and reinsurance counterparties. No public evidence identified of Aviva sourcing goods or services from Israeli-based suppliers, companies operating in Israeli settlements, or settlement industrial zones, nor of any Israeli counterparty in its disclosed supplier/reinsurance registers.

Product Origin, Labeling & Regulatory Compliance

Aviva’s products are financial instruments (insurance, pensions, funds, annuities), distributed principally in the UK, Ireland, and Canada following the 2024–2025 disposal of most international operations; these carry no geographic product-of-origin labelling obligations. No public evidence identified of product lines marketed in or originating from the Occupied Palestinian Territory or Israeli settlements.

Investment, Capital & Financial Exposure

This is the core section for an insurer/asset manager; exposure operates across distinct channels.

1. Israeli sovereign debt (active Aviva Investors decision). On 30 January 2026, Aviva Investors (£262bn AUM) purchased ~$108 million of Israeli government bonds in Israel’s $6 billion international issuance, across three tranches ($45.7m 5yr / $25.7m 10yr / $36.4m 30yr) - the largest UK purchase in Profundo’s dataset and the fifth largest globally.¹ Aviva Investors’ sovereign-bond funds (e.g. its Global Sovereign Bond Fund) are actively managed, so this was a discretionary fixed-income decision, not passive index replication.² Corporate-structure caveat: Aviva plc’s treasury stated “Aviva plc has no exposure to Israeli government debt,” attributing the position to Aviva Investors’ third-party client funds, “which has been significantly reduced since the end of January”; by April 2026 the holding had fallen from $108m to ~$40 million.¹

2. Holdings in arms companies supplying Israel. The March 2025 report Ensuring Genocide (Boycott Bloody Insurance, endorsed by 22 organisations) identified Aviva as the largest investor among five major insurers (51.5% of the total examined), attributing $881 million across 12 of 15 named military-equipment suppliers, concentrated in BAE Systems ($345m), Rolls-Royce ($238.6m), Caterpillar ($106m), and Honeywell ($89.3m) - companies the report links to equipment used by the IDF in Gaza (e.g. BAE’s M109 howitzer).³ A War on Want report similarly identified Aviva holdings; Aviva’s 2018 response committed to engagement without denying the holdings.⁴ Classification note: the report does not separate Aviva Investors’ actively managed client-fund positions from any Aviva plc own-account holdings; BAE/Rolls-Royce are widely held across UK active and passive strategies, and no disclosure at the level needed to determine the active/passive split for these specific positions was identified.

3. DBIO (Don’t Buy Into Occupation) - settlement-linked exposure. Ethical Consumer’s profile cites DBIO V (November 2025) as ranking Aviva the 22nd largest investor among 1,000+ European financial institutions, with over $14.5 billion in shareholdings/bondholdings across 104 settlement-implicated businesses.⁵ This figure likely reflects aggregate Aviva Investors client-AUM exposure to the DBIO target universe rather than own-account exposure. Caveat: the primary DBIO V PDF was not independently readable in this review; the rank and dollar figure originate from Ethical Consumer’s secondary summary and should be verified against the primary DBIO annex.⁶

4. OHCHR settlement database. No public evidence identified that Aviva or Aviva Investors appears on the OHCHR database of business enterprises involved in settlement activity (the database lists operational companies, not financial investors); as an intermediary, Aviva is not subject to direct OHCHR listing.⁷

5. ESG exclusion policy. Aviva Investors’ Baseline Exclusions Policy bars manufacturers of certain controversial weapons, including incendiary weapons using white phosphorus.⁸ Campaigners highlight a tension between this and Aviva’s substantial BAE holding (documented IDF white-phosphorus use of BAE-supplied M109 howitzers in Gaza); Aviva’s position is that its exclusion applies to manufacturers of the white-phosphorus weapon itself, not all customers of systems used with that munition, and that its investments remain “in accordance with the UK legal framework.”⁹ No formal regulatory finding on this question was identified.

Operational Presence & Market Activity

Aviva does not operate in Israel; after successive disposals of overseas insurance operations its footprint is concentrated in the UK, Ireland, and Canada.¹⁰ A UK Companies House entry for “Aviva Israel Ltd” (incorporated December 2025) exists at a London registered-agent address, but its business purpose was not identified in public sources and no Israeli trading or regulatory registration is apparent (possibly a dormant/name-protection entity).¹¹ Aviva Canada explicitly stated “Aviva has no operations in the region.”⁹ No public evidence identified of any Aviva insurance, pension, or savings operation in the Israeli market.

Corporate Structure & Foundational Ties

Aviva plc is incorporated in England and Wales and LSE-listed; its structure is UK-centric, with no Israeli holding companies, joint ventures, or operationally significant Israeli/OPT subsidiaries identified. Aviva Investors is a wholly-owned Aviva plc subsidiary (Companies House no. 02045601).¹² No founding-era or historical tie to Israeli state capital or Israeli financial institutions was identified.

Profit Repatriation & Economic Contribution

Aviva has no commercial operations in Israel from which profits could be repatriated. Its economic contribution to Israel via sovereign-bond purchases is a lending relationship rather than an operational profit stream, and is marginal relative to Israel’s total capital-markets activity; interest income on the Israeli bonds flowed to Aviva Investors’ client accounts, not Aviva’s own P&L, per Aviva’s stated position.¹ No royalty, licensing, or intercompany transfer flows to Israeli entities were identified.

End Notes